In the wake of the RACE Act, identifying and partnering with key stakeholders, namely patient organizations and academia, will enable companies to efficiently overcome key barriers.
This whitepaper offers a high-level orientation around the key barriers to readiness and critical success factors for companies navigating the pediatric oncology space. The primary focus of this whitepaper is on how collaboration with patient organizations will be critical to overcoming the obstacles most companies will encounter.
Together, the elements of this whitepaper aim to support collaboration between industry and patient organizations as a valuable strategy to ensuing readiness for the RACE Act.
Perspectives and Stories from the Pediatric Collaboration Team
The Center for Pediatric Clinical Development (CPCD) is comprised of 11 dedicated staff members who share diverse healthcare and research…
What Does the Future of Childhood Cancer Treatment Look Like?
Now that the RACE for Children Act has come into effect, the drug development industry and patients and their families are optimistic—more drugs will…
Challenges Arise as the Need for Pediatric Research Increases
Many modern providers prescribe off-label treatment to children with “guesstimated” doses, because these drugs have often only been studied in…